Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume.

GeroScience·2026
Same author

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

EBioMedicine·2026
Same author

Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Genetic variation in the glymphatic pathway predicts cognition and neurodegeneration in preclinical Alzheimer's disease.

Research square·2026
Same journal

Unveiling the procoagulant state in Alzheimer's disease: A novel PET imaging strategy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Estimated labor market outcomes of people progressing from preclinical to early-stage Alzheimer's disease in the United States.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Amyloid exacerbates tau and alpha-synuclein pathologies, behavioral impairments, and neuroinflammation in a mixed dementia model.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Multimorbidity burden and patterns associated with DeepBrainNet-derived brain-age gap in dementia-free older adults: A community-based study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Reply to "Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities".

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Shifting the emphasis of brain health literacy from individuals to systems to reduce inequalities.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
関連記事をすべて見る

関連する実験動画

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

バイオマーカー

Ying Xia1,2, Vincent Dore3,4, Jurgen Fripp1

  • 1CSIRO Health and Biosecurity, Australian E-Health Research Centre, Brisbane, QLD, Australia.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
まとめ
この要約は機械生成です。

アルツハイマー病（AD）の進行は、早期段階では脳萎縮を伴わないアミロイドβ（Aβ）の蓄積を示す。しかし、記憶力の低下はAβの蓄積と関連しており、構造的変化に先行する神経機能障害を示唆している。

キーワード:
アルツハイマー病アミロイドβ記憶喪失脳萎縮神経機能障害

さらに関連する動画

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

関連する実験動画

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学分野:

  • 神経科学
  • 神経学
  • 生物医学イメージング

背景:

  • アルツハイマー病（AD）は、アミロイドβ（Aβ）沈着とコリン作動性基底前脳（BF）系の機能障害を特徴とする。
  • 新規ADにおける亜閾値Aβ蓄積の早期病理学的変化と認知的影響は不明なままである。

主な方法:

  • オーストラリア画像、バイオマーカー、ライフスタイル（AIBL）研究のCU者408名（当初Aβ陰性）のデータを使用した。
  • 15年間にわたるBF亜領域および海馬の体積変化、および認知複合スコアを分析するために線形混合効果モデルを使用した。
  • Aβ+（新規AD）への進行者とAβ-（安定CU）のままの参加者を層別化した。

結論:

  • 新規ADにおけるアミロイドβ蓄積は、基底前脳および海馬における脳萎縮の加速なしに発生する。
  • 観察されたAβ蓄積とエピソード記憶喪失との関連は、Aβ関連神経機能障害が検出可能な脳体積変化に先行する可能性を示唆している。